由于ADHD/儿科产品的营销减少,Aytu BioPharma的2026年第二季度收入下降到1520万美元,因为重点转移到其新型抗抑郁药EXXUA,该药在2025年12月推出,并产生了2020万美元的收入. Aytu BioPharma's Q2 2026 revenue fell to $15.2M, driven by reduced marketing for ADHD/pediatric products as focus shifted to its new antidepressant EXXUA, which launched in Dec. 2025 and generated $0.2M in revenue.

Aytu BioPharma报告说,2026年财政年度第二季度财政净收入为1 520万美元,低于一年前的1 620万美元,原因是由于重点转移到EXXUA,其ADHD和儿科产品的营销量减少,而EXXUA是林业发展局新核准的5-HT1A主要抑郁症抗药剂师。 Aytu BioPharma reported fiscal 2026 second-quarter net revenue of $15.2 million, down from $16.2 million a year earlier, due to reduced marketing for its ADHD and pediatric products as focus shifted to EXXUA, a newly FDA-approved 5-HT1A agonist for major depressive disorder. 该药物于2025年12月启动,在季度期间贡献了20万美元的收入。 The drug launched in December 2025 and contributed $0.2 million in revenue during the quarter. 尽管净亏损为1060万美元,主要来自衍生品担保负债,调整后的EBITDA将是正值,标志着连续第11个季度没有启动成本. Despite a net loss of $10.6 million, largely from a derivative warrant liability, adjusted EBITDA would have been positive, marking the 11th consecutive quarter without launch costs. 该公司报告有3 000万美元现金、全国40多名代表的销售力量以及27个州的早期处方活动,其RxConnect方案支持患者获得治疗服务。 The company reported $30 million in cash, a nationwide sales force of over 40 reps, and early prescription activity across 27 states, with patient access supported by its RxConnect program.